sarclisa
sanofi winthrop industrie - isatuximab - viacnásobný myelóm - antineoplastické činidlá - sarclisa is indicated: in combination with pomalidomide and dexamethasone, for the treatment of adult patients with relapsed and refractory multiple myeloma (mm) who have received at least two prior therapies including lenalidomide and a proteasome inhibitor (pi) and have demonstrated disease progression on the last therapy. in combination with carfilzomib and dexamethasone, for the treatment of adult patients with multiple myeloma who have received at least one prior therapy (see section 5.
cabazitaxel accord
accord healthcare s.l.u. - cabazitaxel - prostatic neoplasms, kastrácia-odolný - antineoplastické činidlá - treatment of patients with hormone refractory metastatic prostate cancer previously treated with a docetaxel-containing regimen.
jevtana
sanofi winthrop industrie - cabazitaxel - prostatické nádory - antineoplastické činidlá - jevtana v kombinácii s prednizónom alebo prednizolónom je indikovaná na liečbu pacientov s metastatickým karcinómom prostaty refraktérneho pôvodu, ktorý bol predtým liecený režimom obsahujúcim docetaxel.
eleber 60 mg koncentrát a rozpúšťadlo na infúzny roztok
zentiva, k.s., Česká republika - kabazitaxel - 44 - cytostatica
cabazitaxel fresenius kabi 20 mg/ml
fresenius kabi s.r.o., Česká republika - kabazitaxel - 44 - cytostatica
cabazitaxel ever pharma 10 mg/ml koncentrát na infúzny roztok
ever valinject gmbh, rakúsko - kabazitaxel - 44 - cytostatica
cabazitaxel msn
msn labs europe limited, malta - kabazitaxel - 44 - cytostatica